Vaxcyte Inc. (PCVX): Price and Financial Metrics
PCVX Price/Volume Stats
|Current price||$52.45||52-week high||$54.97|
|Prev. close||$52.19||52-week low||$20.49|
|Day high||$52.63||Avg. volume||718,975|
|50-day MA||$49.43||Dividend yield||N/A|
|200-day MA||$46.18||Market Cap||4.92B|
PCVX Stock Price Chart Interactive Chart >
Vaxcyte Inc. (PCVX) Company Bio
Vaxcyte, Inc. engages in development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, Ashish Khanna and Jeff Fairman on November 27, 2013 and is headquartered in San Francisco, CA.
PCVX Latest News Stream
|Loading, please wait...|
PCVX Latest Social Stream
View Full PCVX Social Stream
Latest PCVX News From Around the Web
Below are the latest news stories about VAXCYTE INC that investors may wish to consider to help them evaluate PCVX as an investment opportunity.
SAN CARLOS, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference in New York on Tuesday, September 26, 2023 at 11:40 a.m. ET / 8:40 a.m. PT. A live webcast of the fireside chat can be accessed through
Codexis (CDXS) transfers the leasing rights of its San Carlos, CA location to Vaxcyte to focus on technology development, inducing cost savings, to extend its cash runway to mid-2026. The stock rises 7%.
Vaxcyte and Codexis signed leases within weeks of each other in early 2021 at Alexandria Real Estate Equities' Alexandria District for Science & Technology in San Carlos.
-- Advanced Ongoing VAX-24 Phase 2 Infant Study to Second Stage, Dosing First New Participants in July 2023; Topline Data from Primary Immunization Series Expected by 2025 -- -- Completed Phase 2 VAX-24 Adult Program for the Prevention of Invasive Pneumococcal Disease (IPD); Topline Phase 3 Data Expected in 2025 -- -- VAX-31 Adult Investigational New Drug (IND) Application Clearance Expected in Fourth Quarter of 2023; Topline Phase 1/2 Data Expected in 2024 -- -- $1.4 Billion in Cash, Cash Equiv
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Initiation of Stage 2 Approved by Independent Data Safety Monitoring Board Following Review of Stage 1 Safety and Tolerability Data -- -- The Stage 2 Portion of VAX-24 Infant Study Will Include Prevnar 20® (PCV20) as Study Comparator -- -- Company Expects to Announce Topline Data from Primary Immunization Series by 2025, Followed by Topline Data from Booster Dose Approximately Nine Months Later -- SAN CARLOS, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-s
PCVX Price Returns